PHAS
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
PHAS
Delisted
PHAS was delisted on the 2nd of November, 2022.
19 hedge funds and large institutions have $65.8M invested in PhaseBio Pharmaceuticals, Inc. Common Stock in 2019 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
Holders
19
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$2.9M | |
| 2 | +$898K | |
| 3 | +$725K | |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
+$600K |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$559K |
Top Sellers
| 1 | -$2.46M | |
| 2 | -$592K | |
| 3 | -$351K | |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$261K |
| 5 |
LCM
Laurion Capital Management
New York
|
-$167K |